Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.8M
-
Number of holders
-
112
-
Total 13F shares, excl. options
-
60.2M
-
Shares change
-
-1.75M
-
Total reported value, excl. options
-
$653M
-
Value change
-
-$19.3M
-
Put/Call ratio
-
0.47
-
Number of buys
-
46
-
Number of sells
-
-57
-
Price
-
$10.85
Significant Holders of Theravance Biopharma, Inc. - Common Stock (TBPH) as of Q1 2023
137 filings reported holding TBPH - Theravance Biopharma, Inc. - Common Stock as of Q1 2023.
Theravance Biopharma, Inc. - Common Stock (TBPH) has 112 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 60.2M shares
.
Largest 10 shareholders include BAUPOST GROUP LLC/MA (10.4M shares), Weiss Asset Management LP (7.46M shares), Madison Avenue Partners, LP (7.01M shares), VANGUARD GROUP INC (5.63M shares), BlackRock Inc. (5.14M shares), Irenic Capital Management LP (2.76M shares), Park West Asset Management LLC (1.9M shares), BANK OF AMERICA CORP /DE/ (1.78M shares), FMR LLC (1.71M shares), and Newtyn Management, LLC (1.53M shares).
This table shows the top 112 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.